Dr. Zhi-Yao He, an associate professor and clinical pharmacist position, is currently engaging in research at the West China Hospital, Sichuan University, Chengdu, Sichuan, China. His research focus is on developing and improving gene delivery strategies or gene therapy methods for diseases, especially for cancer. Dr. Zhi-Yao He is the associate editor of Biointerface Research in Applied Chemistry, Frontiers in Pharmacology, Frontiers in Genetics, the executive guest editor of Current Gene Therapy, and an editorial member of Current Gene Therapy, PLoS One, Annals of Translational Medicine, and Chinese Chemical Letters. He has been invited as a peer-reviewer by over 70 international journals including J Am Chem Soc (JACS), Biomaterials, ACS Cent Sci, Signal Transduct Target Ther, Hum Gene Ther, etc. As a co-author, he has published over 60 peer-reviewed papers in about three dozen international journals, e.g., Biotechnol Adv, Signal Transduct Target Ther, J Control Release, Cell Res, etc. In addition, Dr. Zhi-Yao He is an international member of ASGCT (American Society of Gene and Cell Therapy) and ACS (American Chemical Society), and a senior member of some Chinese academic and technical organizations. He is a committee member of the Oncology Clinical Pharmacy for the Chinese Anti-Cancer Association, and a committee member of Genome Editing Technologies in the China Medicinal Biotech Association.
Dr. Zhi-Yao He, an associate professor and clinical pharmacist position, is currently engaging in research at the West China Hospital, Sichuan University, Chengdu, Sichuan, China. His research focus is on developing and improving gene delivery strategies or gene therapy methods for diseases, especially for cancer. Dr. Zhi-Yao He is the associate editor of Biointerface Research in Applied Chemistry, Frontiers in Pharmacology, Frontiers in Genetics, the executive guest editor of Current Gene Therapy, and an editorial member of Current Gene Therapy, PLoS One, Annals of Translational Medicine, and Chinese Chemical Letters. He has been invited as a peer-reviewer by over 70 international journals including J Am Chem Soc (JACS), Biomaterials, ACS Cent Sci, Signal Transduct Target Ther, Hum Gene Ther, etc. As a co-author, he has published over 60 peer-reviewed papers in about three dozen international journals, e.g., Biotechnol Adv, Signal Transduct Target Ther, J Control Release, Cell Res, etc. In addition, Dr. Zhi-Yao He is an international member of ASGCT (American Society of Gene and Cell Therapy) and ACS (American Chemical Society), and a senior member of some Chinese academic and technical organizations. He is a committee member of the Oncology Clinical Pharmacy for the Chinese Anti-Cancer Association, and a committee member of Genome Editing Technologies in the China Medicinal Biotech Association.